INTRODUCTION 6 5
The intrinsic capacity of glioblastoma (GBM) tumor cells to infiltrate normal brain gene expression subtype classification through revised gene signatures and proposed 1 0 0 analytical methodology. Our results suggested that the tumor microenvironment 1 0 1 interferes with expression based classification of GBM, both at the primary disease 1 0 2 stage as well as at disease recurrence, and suggest a role for the 1 0 3 macrophage/microglia in treatment response. We set out to elucidate the tumor-intrinsic and tumor microenvironment independent 1 0 8 transcriptional heterogeneity of GBMs. We performed a pairwise gene expression 1 0 9 comparison of independent set of GBMs and the derivative glioma sphere-forming cells 1 1 0 (GSCs) (n = 37) (Galli et al., 2004) . In total, 5,334 genes were found to be significantly 1 1 1 higher expressed in parental GBMs relative to derived GSCs that could be attributed by 1 1 2 the tumor associated GBM microenvironment (Figure 1A) . To focus the analysis on the 1 1 3 tumor-intrinsic transcriptome, these genes were filtered from further analysis. GBMs Research et al., 2015; Ceccarelli et al., 2016; Noushmehr et al., 2010) . Using the 1 1 7 filtered gene set, we performed consensus non-negative matrix factorization clustering PN GBMs, respectively (Figure S1) . Consequently, we labeled the groups as CL, MES 1 2 3 and PN. None of the three subgroups was enriched for the NE class, suggesting its 1 2 4 neural phenotype is non-tumor specific. The NE group has previously been related to 1 2 5 the tumor margin where normal neural tissue is more likely to be present (Gill et al., was the only subtype to lack characteristic gene abnormalities (Brennan et al., 2013;  1 2 8 Verhaak et al., 2013) . To be able to classify external GBM samples, we implemented a 1 2 9 single sample gene set enrichment analysis (ssGSEA) based equivalent distribution 1 3 0 resampling classification strategy using 70-gene signatures for each subgroup (Table   1 3 1 S1)( Figure 1D) , to assign each sample three empirical classification p-values by which 1 3 2 we determined the significantly activated subtype(s) in the samples. We prepared an R-1 3 3 library to facilitate others to evaluate our approach (Supplementary File 1). Using this 1 3 4 method we found that the stability of cluster assignments of 144 TCGA GBM samples 1 3 5 profiled using both RNA sequencing and Affymetrix U133A microarrays was 95% 1 3 6 concordance ( Figure S2 , Table S2 ). This was an improvement over the 77% subtype 1 3 7 concordance determined using previously reported methods (Verhaak et al., 2010b) .
We evaluated the distribution of somatic variants across all the three molecular test p-value=0.008) (Figure 7A) . This observation was further validated by comparing 3 3 4 seven hypermutated primary GBMs to 238 non-hypermutated GBMs (median 7.0‰ vs 3 3 5 0‰; Wilcoxon rank test p-value=0.031)( Figure 7B) . The majority (61%) of non-3 3 6 hypermutated primary GBMs showed predicted CD8+ T cell fractions equal to zero. The 3 3 7 observation suggests that patients with hypermutated tumors are more likely to benefit 3 3 8 from CD8+ T cell antitumor immunity. Preclinical studies suggested radiation may increase the recruitment of T cells in 3 4 0 the tumor microenvironment (Deng et al., 2014; Zeng et al., 2013) . We compared the 3 4 1 microenvironment of primary GBM treated with radiation therapy and separated short 3 4 2 term relapse (PFS > 6 months, n = 27) from late relapse (PFS > 12 months, n = 21).
4 3
Evaluating the gene signature based presence of M2 macrophages and CD4+ T cells received radiotherapy, we observed no significant difference between primary tumors 3 4 6 with short-term and long-term relapse but found a significant increase after radiation at resistance to radiotherapy (Meng et al., 2010; Ruffell and Coussens, 2015) and 3 4 9 macrophage targeting immunotherapy (Pyonteck et al., 2013; Ries et al., 2014 ) may 3 5 0 play a radiosensitizing role. The increasing of CD4+ T cells at recurrence for short term 3 5 1 relapse tumors points towards inhibiting CTLA-4 as adjuvant therapy to radiation. C-1404-056-572). Affymetrix CEL files of 39 pairs of initial and recurrent glioma were 4 2 0 retrieved from the Gene Expression Omnibus (GEO accession GSE4271, GSE42670, 4 2 1 GSE62153) (Joo et al., 2013; Kwon et al., 2015; Phillips et al., 2006) . The expression 4 2 2 2 0 profiles of the 23 pairs from GSE4271 were determined using Affymetrix HG-U133 4 2 3
Collection of pairs of primary and recurrent glioma samples
GeneChips, the 1 pairs from GSE42670 were analyzed using the Affmetrix HuGene-1- were discarded from the gene list for developing tumor-specific molecular subtypes. obtains its expression level by randomly selecting an expression value of the same 4 9 5 gene in the remainder of the samples. Then, the three ssGSEA scores for each 4 9 6 signature were calculated. Following this procedure we generated a large number 4 9 7
(>1,000,000) of random ssGSEA scores for each subtype, to build the null distribution multiple datasets with different sample sizes, we found the resampling generated defined as:
Similarly, the accumulative distance between non-dominant subtypes (ADNS) as:
Obviously, the ADDS and ADNS are positive and negative correlated with single 5 1 2 activation, respectively. Hence, we defined the simplicity score by combing ADDS and 5 1 3
ADNS together and corrected with a constant
as follows:
Tumor purity assessment 5 1 6
The ESTIMATE package was used to evaluate tumor purity on the basis of the where the fraction of stromal cells and immune cells in each sample were represented 5 1 9
by stromal score and immune score respectively, and the mixed fraction of both stromal the order that they were acquired. Each tissue was enzymatically and mechanically 5 2 9 dissociated into single cells and grown in DMEM/F12 media supplemented with B27 5 3 0 (Invitrogen), EGF (20 ng/ml), and bFGF (20 ng/ml), resulting in neurosphere growth. All Lysates were prepared from fresh frozen sections using RPPA lysis buffer (1% Triton X- , 
